Details of the Metabolic Reaction (MR)

General Information of This Metabolic Reaction (MR) (ID: MR000146)
Formula
SVG example
Tautomerisation
Reactant Almotriptan malate metabolite M3 Product ACP-5461
Reactant Info Product Info
Metabolic Type Other reaction - Tautomerisation
Other MR(s) Related to The Reactant of This MR
Other MR(s) That Produce The Reactant of This MR
MR ID Reactant Product MR Type Related Drug REF
MR008988 Almogran 2-OH-almotriptan Oxidation - Aliphatic hydroxylation Almogran [1]
MR000153 Almotriptan malate Almotriptan malate metabolite M3 Oxidation - Pyrrolidine Oxidation Almotriptan malate [2]
Other MR(s) That Metabolize The Reactant of This MR
MR ID Reactant Product MR Type Related Drug REF
MR008989 2-OH-almotriptan Almogran metabolite A2 Unclear - Unclear Almogran [3]
Other MR(s) Related to The Product of This MR
Other MR(s) That Produce The Product of This MR
MR ID Reactant Product MR Type Related Drug REF
MR001006 SCH 57871 ACP-5461 Oxidation - Oxidation Ezetimibe [4]
MR000016 ACP-5531 ACP-5461 Oxidation - N-Dealkylation Acalabrutinib [5]
Other MR(s) That Metabolize The Produtc of This MR
MR ID Reactant Product MR Type Related Drug REF
MR000147 ACP-5461 LAS 31911 Other reaction - Dehydration Almotriptan malate [2]
References
1 Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. Curr Med Chem. 2009;16(31):4066-218.
2 Clinical pharmacokinetics of almotriptan, a serotonin 5-HT(1B/1D) receptor agonist for the treatment of migraine. Clin Pharmacokinet. 2005;44(3):237-46.
3 Almotriptan, a new anti-migraine agent: a review. CNS Drug Rev. 2002 Fall;8(3):217-34.
4 Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet. 2005;44(5):467-94.
5 Bioavailability, Biotransformation, and Excretion of the Covalent Bruton Tyrosine Kinase Inhibitor Acalabrutinib in Rats, Dogs, and Humans Drug Metab Dispos. 2019 Feb;47(2):145-154. doi: 10.1124/dmd.118.084459.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.